Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tumor-infiltrating lymphocytes
- Development stage
- Unknown
- Lead developer
- Karolinska University Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Tumor-infiltrating lymphocytes (TILs) developed by Karolinska University Hospital are an autologous adoptive cell therapy being investigated for the treatment of metastatic melanoma. The therapy involves harvesting naturally occurring T cells from a patient's resected tumor tissue, followed by their activation and large-scale expansion ex vivo. These expanded TILs are then re-infused into the patient after a non-myeloablative lymphodepleting conditioning regimen, typically consisting of cyclophosphamide and fludarabine. To support the survival and anti-tumor activity of the infused cells, systemic interleukin-2 (IL-2) is administered. In specific clinical protocols at Karolinska, this TIL therapy is also evaluated in combination with an autologous dendritic cell vaccine to further enhance the immune response against melanoma-specific antigens.
- Other names
- Adoptive T cell transferT cellsTumor-infiltrating lymphocytes
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Tumor-infiltrating lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-infiltrating lymphocytes.